ResMed Inc.: Beat — EPS $2.91, Revenue $1.41B
Earnings BeatQ1 2027 · After-market
Did ResMed Inc. (RMD) beat earnings today?
Yes, ResMed Inc. (RMD) beat Wall Street analyst expectations for Q1 2027, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+8.99% surprise
$2.91Actual
Expected: $2.67
vs. year ago +14.0%
Total Revenue+1.79% surprise
$1.41BActual
Expected: $1.39B
vs. year ago +6.0%
Released Oct 29 · 4:05 PM ET
Earning Report
| Metric | Q1 2027 | Q1 2026 | YoY Change % |
|---|---|---|---|
| Revenue | $1.41B | $1.34B | +6.0% |
| Revenue detail — reported lines | |||
| └─Americas Sleep Devices | $436.00M | $405.00M | +8.0% |
| └─Total Americas Sleep and Breathing Health | $833.00M | $775.00M | +8.0% |
| └─Rest of World Sleep Devices | $280.00M | $250.00M | +12.0% |
| └─Total Rest of World Sleep and Breathing Health | $426.00M | $395.00M | +8.0% |
| └─Total Sleep Devices | $716.00M | $655.00M | +9.0% |
| └─Total Masks and other | $540.00M | $489.00M | +10.0% |
| └─Total Sleep | $1.26B | $1.14B | +10.0% |
| └─Total Life Support Devices | $4.00M | $25.00M | -84.0% |
| └─Total Sleep and Breathing Health | $1.26B | $1.17B | +8.0% |
| └─Residential Care Software | $155.00M | $166.00M | -7.0% |
| GAAP Basic EPS | $2.93 | $2.38 | +23.1% |
| GAAP Diluted EPS | $2.92 | $2.37 | +23.0% |
| Non-GAAP Diluted EPS | $2.91 | $2.55 | +14.0% |
| Net Income | $418.41M | $348.54M | +20.0% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY 2027 Guidance as of October 29, 2026 |
|---|---|---|
| Revenue | — | $5.75-$5.85B (Core Constant Currency: 5-7% growth, prev. $5.75-$5.85B) |
| Non-GAAP Diluted EPS | — | $12.00-$12.25 (prev. $12.00-$12.25) |
Business Highlights
- ➤Closed the previously announced MatrixCare business divestiture.
- ➤Launched AirTouch F40 fabric CPAP masks in the United States.
- ➤Partnered with Eight Sleep to connect its technology with Resmed sleep insights.
- ➤Partnered with 23XI Racing driver Tyler Reddick to increase sleep apnea awareness.
- ➤Appointed Carol Burt as Lead Director, effective November 15, 2026.
- ➤Returned more than $1.0B to shareholders through repurchases and dividends.
- ➤Declared a quarterly cash dividend of $0.66 per share.
- ➤Resmed’s digital health solutions serve people in 140 countries.
Management Commentary
Mick Farrell, Chairman and CEO
“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business. Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%. Our strong free cash flow and the proceeds from our divestiture of MatrixCare enabled us to both invest in innovation and return more than $1 billion to shareholders during the quarter.”
Mick Farrell, Chairman and CEO
“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”